Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy for borderline resectable pancreatic cancer : Outcomes and prognostic radiotherapeutic factors.
{"title":"Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy for borderline resectable pancreatic cancer : Outcomes and prognostic radiotherapeutic factors.","authors":"Takahiro Iwai, Michio Yoshimura, Yuka Ono, Ayaka Ogawa, Ryo Ashida, Toshihiko Masui, Kazuyuki Nagai, Takayuki Anazawa, Yousuke Kasai, Kei Yamane, Etsuro Hatano, Masashi Kanai, Akihisa Fukuda, Hiroyoshi Isoda, Takashi Mizowaki","doi":"10.1007/s00066-025-02433-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the outcome and prognostic factors for borderline resectable pancreatic cancer (BRPC) patients treated with neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy (NAC-MH-IMRT).</p><p><strong>Methods: </strong>Patients with BRPC treated with NAC-MH-IMRT at 42 Gy in 15 fractions between February 2013 and June 2021 were evaluated. The overall survival (OS), progression-free survival (PFS), cumulative incidence of locoregional failure and distant metastases, association dose-volume indices, Evans grade for pathological response, and toxicities were evaluated.</p><p><strong>Results: </strong>A total of 66 patients met the inclusion criteria, and the median follow-up period was 23.9 months. In all, 48 patients underwent pancreatectomy, and margin-negative resection was achieved in 44 patients (91.7%). The median survival and PFS times were 34.8 months and 12.0 months, respectively, for the whole cohort. The 2‑year cumulative incidences of locoregional recurrence and distant metastases in the resected group were 25.7 and 52.8%, respectively. From the Mann-Whitney U test, the minimum dose of the primary gross tumor volume (GTV<sub>min</sub>) of the group with Evans grade ≥ 2b was statistically higher than that of the other group (38.6 Gy vs. 37.3 Gy, p = 0.005). However, this was not associated with reduced cumulative incidence of locoregional failure. No patient had grade ≥ 3 acute gastrointestinal toxicity.</p><p><strong>Conclusion: </strong>NAC-MH-IMRT for BRPC resulted in good survival outcomes and margin-negative resection rates. High GTV<sub>min</sub> was associated with good pathological response; however, improvement of local control requires further investigation.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"1031-1043"},"PeriodicalIF":2.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Strahlentherapie und Onkologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00066-025-02433-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To evaluate the outcome and prognostic factors for borderline resectable pancreatic cancer (BRPC) patients treated with neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy (NAC-MH-IMRT).
Methods: Patients with BRPC treated with NAC-MH-IMRT at 42 Gy in 15 fractions between February 2013 and June 2021 were evaluated. The overall survival (OS), progression-free survival (PFS), cumulative incidence of locoregional failure and distant metastases, association dose-volume indices, Evans grade for pathological response, and toxicities were evaluated.
Results: A total of 66 patients met the inclusion criteria, and the median follow-up period was 23.9 months. In all, 48 patients underwent pancreatectomy, and margin-negative resection was achieved in 44 patients (91.7%). The median survival and PFS times were 34.8 months and 12.0 months, respectively, for the whole cohort. The 2‑year cumulative incidences of locoregional recurrence and distant metastases in the resected group were 25.7 and 52.8%, respectively. From the Mann-Whitney U test, the minimum dose of the primary gross tumor volume (GTVmin) of the group with Evans grade ≥ 2b was statistically higher than that of the other group (38.6 Gy vs. 37.3 Gy, p = 0.005). However, this was not associated with reduced cumulative incidence of locoregional failure. No patient had grade ≥ 3 acute gastrointestinal toxicity.
Conclusion: NAC-MH-IMRT for BRPC resulted in good survival outcomes and margin-negative resection rates. High GTVmin was associated with good pathological response; however, improvement of local control requires further investigation.
期刊介绍：
Strahlentherapie und Onkologie, published monthly, is a scientific journal that covers all aspects of oncology with focus on radiooncology, radiation biology and radiation physics. The articles are not only of interest to radiooncologists but to all physicians interested in oncology, to radiation biologists and radiation physicists. The journal publishes original articles, review articles and case studies that are peer-reviewed. It includes scientific short communications as well as a literature review with annotated articles that inform the reader on new developments in the various disciplines concerned and hence allow for a sound overview on the latest results in radiooncology research.
Founded in 1912, Strahlentherapie und Onkologie is the oldest oncological journal in the world. Today, contributions are published in English and German. All articles have English summaries and legends. The journal is the official publication of several scientific radiooncological societies and publishes the relevant communications of these societies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
